Drug Trial Radar · NCT05513625
Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 13, 2020
Primary completion
Oct 13, 2020
Study completion Oct 13, 2020
Sponsor
- Lead sponsor
- AiCuris Anti-infective Cures AGIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.
Conditions
- HSV Infection
Interventions
PritelivirDrug
oral administration
ESO and pritelivirDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK - CmaxTime frame: 15 days
- PK - AUC(0-infinity) and AUC(0-last)Time frame: 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.